Arrowstreet Capital
PVLA

Arrowstreet Capital’s Palvella Therapeutics PVLA Stock Holding History

Arrowstreet Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-228
Closed -$56K – 2560
2020
Q2 		$56K Buy
+228
New +$53.3K ﹤0.01% 2250
2019
Q2 		– Sell
-5,252
Closed -$1.41M – 1757
2019
Q1 		$1.41M Sell
5,252
-2,327
-31% -$553K ﹤0.01% 1215
2018
Q4 		$1.61M Sell
7,579
-3,269
-30% -$1.01M ﹤0.01% 854
2018
Q3 		$4.86M Sell
10,848
-1,876
-15% -$815K 0.01% 513
2018
Q2 		$5.16M Sell
12,724
-148
-1% -$70.4K 0.01% 539
2018
Q1 		$7.02M Buy
12,872
+7,292
+131% +$4.51M 0.02% 512
2017
Q4 		$3.37M Buy
+5,580
New +$2.59M 0.01% 694

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital's PVLA Position: Q3 2020 in Review

Arrowstreet Capital sold out of Palvella Therapeutics (PVLA) in Q3 2020, closing a stake of 228 shares — an estimated $56K sold.

Arrowstreet Capital first reported a position in PVLA in Q4 2017 and held it in 7 quarters. The position peaked at $7.02M in Q1 2018. 88 funds tracked by Wall St. Rank hold PVLA as of Q3 2020.

  • Arrowstreet Capital reported no remaining Palvella Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 228 Palvella Therapeutics shares in Q3 2020, an estimated $56K.
  • Arrowstreet Capital first reported a position in Palvella Therapeutics in Q4 2017 and held it in 7 quarters.
  • Arrowstreet Capital's Palvella Therapeutics position peaked at $7.02M in Q1 2018.
  • 88 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.